Loading…
← CockpitCompetitor Analysis › 301101.SZ Mingyue Optical Lens Co., Ltd. Class AOpen in the cockpit ↗

Mingyue Optical Lens Co., Ltd. Class A301101.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 97
Mkt cap
$1.07B
US dollars, full cap
Free float
35%
of shares outstanding
$/day
$43.9M
20-day average traded
Fwd P/E
31.6×
forward earnings
ROIC−WACC
+29.1 pp
WACC 6.8%
Hurdle
+0 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥36.04
1D-4.4%
1W-7.6%
1M+17.7%
3M+22.3%
6M-4.5%
YTD-13.0%
1Y-16.4%
ATR %4.8%
52w lowhigh27.8% off high

What Mingyue Optical Lens does

Employees: 1,066

Mingyue Optical Lens at a glance

Size Mingyue Optical Lens (301101.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.07B, the 2029th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥36.04 on 18 Nov 2026.

Performance Over six months the shares fell 4.5%, against -8.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 14.5% over the last twelve months (peer median +10.0%); the operating margin is 25.3% (peer median 11.8%).

Valuation It trades at 31.6× forward earnings against a peer median of 18.4× (3rd most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 29.1 points above its cost of capital (6.8% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026301101.SZ 98Peer median 92
Six months, rebased to 100: Mingyue Optical Lens against the median of its 20 peers (local-currency closes).

Mingyue Optical Lens financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥931MCN¥821MCN¥764MCN¥742MCN¥617M
Revenue growth—+8%+3%+20%—
Gross profitCN¥562MCN¥445MCN¥422MCN¥410MCN¥316M
EBITDAn/aCN¥264MCN¥239MCN¥218MCN¥165M
Net incomeCN¥220MCN¥193MCN¥177MCN¥158MCN¥136M
Free cash flowCN¥179MCN¥207MCN¥179MCN¥155MCN¥95.0M
Capital expenditureCN¥93.2MCN¥96.8MCN¥70.8MCN¥81.4MCN¥77.5M
Total debtCN¥2.53MCN¥49.5MCN¥4.01MCN¥6.81MCN¥9.57M

Quarterly statements and history in the cockpit →

Mingyue Optical Lens competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%688622IARTSIBN214150IRMDATECDRTSCSTLEUZ6000553010216523300406300685300206688161CBLL3001437730301101.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Mingyue Optical Lens is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×IART214150IRMDATECEUZ65233004063006853002066881613001437730301101.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mingyue Optical Lens is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%IART214150IRMDCSTLEUZ30102165233004063002066881613001437730301101.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Mingyue Optical Lens is the large dot.

Mingyue Optical Lens competitors and peer comparison

How Mingyue Optical Lens compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mingyue Optical Lens against its 20 peers (data as of 18 Nov 2026)
Measure301101.SZPeer medianRank in peer set
1-month return+17.7%-6.0%highest of 21
6-month return-4.5%-8.9%9th highest of 20
Distance from 52-week high-27.8%-29.0%11th highest of 21
Revenue growth (TTM)+14.5%+10.0%6th highest of 19
Operating margin25.3%11.8%8th highest of 20
Forward P/E31.6×18.4×3rd most expensive of 13
Growth the price implies (Req g, 7 yrs)8.8%6.9%6th most demanding of 14
Growth delivered (Del g)+8.8%+10.4%6th lowest of 14
Hurdle (Req g minus delivered)+0.0 pp-3.0 pp6th most demanding of 14
ROIC minus cost of capital+29.1 pp+1.5 pp3rd highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%

Questions

Which companies are Mingyue Optical Lens's closest peers?
The cockpit's peer set: Guangzhou Hexin Instrument (688622.SS), Integra LifeSciences (IART), SI-BONE (SIBN), CLASSYS (214150.KS), Freenome (FRNM), IRadimed (IRMD), Alphatec (ATEC), Alpha Tau Medical (DRTS).
Is Mingyue Optical Lens expensive compared with its peers?
On forward p/e it trades at 31.6× against a peer median of 18.4×, 3rd most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Mingyue Optical Lens stock performed?
Over six months to 18 Nov 2026 the shares returned -4.5% against -8.9% for the median peer; over one year -16.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.